SG11202010911WA - Methods and compositions for treating chronic urticaria - Google Patents
Methods and compositions for treating chronic urticariaInfo
- Publication number
- SG11202010911WA SG11202010911WA SG11202010911WA SG11202010911WA SG11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA SG 11202010911W A SG11202010911W A SG 11202010911WA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- treating chronic
- chronic urticaria
- urticaria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667242P | 2018-05-04 | 2018-05-04 | |
| US201962788719P | 2019-01-04 | 2019-01-04 | |
| US201962797817P | 2019-01-28 | 2019-01-28 | |
| US201962803211P | 2019-02-08 | 2019-02-08 | |
| US201962806657P | 2019-02-15 | 2019-02-15 | |
| PCT/US2019/030523 WO2019213468A1 (en) | 2018-05-04 | 2019-05-03 | Methods and compositions for treating chronic urticaria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010911WA true SG11202010911WA (en) | 2020-12-30 |
Family
ID=68386174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010911WA SG11202010911WA (en) | 2018-05-04 | 2019-05-03 | Methods and compositions for treating chronic urticaria |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210246205A1 (en) |
| EP (1) | EP3788078A4 (en) |
| JP (2) | JP2021523117A (en) |
| KR (1) | KR20210005245A (en) |
| CN (1) | CN112384535A (en) |
| AU (1) | AU2019262167A1 (en) |
| BR (1) | BR112020022236A2 (en) |
| CA (1) | CA3099338A1 (en) |
| MX (1) | MX2020011377A (en) |
| SG (1) | SG11202010911WA (en) |
| WO (1) | WO2019213468A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200016232A (en) | 2017-05-05 | 2020-02-14 | 알라코스 인크. | Methods and compositions for treating allergic eye diseases |
| TW202214703A (en) * | 2020-07-10 | 2022-04-16 | 大陸商上海濟煜醫藥科技有限公司 | An anti-ige engineered antibody and the use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105849280B (en) * | 2013-10-23 | 2020-11-06 | 豪夫迈·罗氏有限公司 | Methods of diagnosing and treating eosinophilic disorders |
| CN114044825A (en) * | 2013-12-09 | 2022-02-15 | 爱乐科斯公司 | anti-Siglec-8 antibodies and methods of use thereof |
| WO2015131155A1 (en) * | 2014-02-28 | 2015-09-03 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
| US10604577B2 (en) * | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
-
2019
- 2019-05-03 SG SG11202010911WA patent/SG11202010911WA/en unknown
- 2019-05-03 CN CN201980044867.8A patent/CN112384535A/en active Pending
- 2019-05-03 KR KR1020207034828A patent/KR20210005245A/en unknown
- 2019-05-03 BR BR112020022236-4A patent/BR112020022236A2/en unknown
- 2019-05-03 AU AU2019262167A patent/AU2019262167A1/en active Pending
- 2019-05-03 US US17/051,766 patent/US20210246205A1/en not_active Abandoned
- 2019-05-03 JP JP2020561727A patent/JP2021523117A/en not_active Withdrawn
- 2019-05-03 MX MX2020011377A patent/MX2020011377A/en unknown
- 2019-05-03 CA CA3099338A patent/CA3099338A1/en active Pending
- 2019-05-03 WO PCT/US2019/030523 patent/WO2019213468A1/en active Application Filing
- 2019-05-03 EP EP19796049.5A patent/EP3788078A4/en not_active Withdrawn
-
2024
- 2024-02-19 JP JP2024022749A patent/JP2024045612A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210005245A (en) | 2021-01-13 |
| CA3099338A1 (en) | 2019-11-07 |
| JP2024045612A (en) | 2024-04-02 |
| JP2021523117A (en) | 2021-09-02 |
| WO2019213468A1 (en) | 2019-11-07 |
| CN112384535A (en) | 2021-02-19 |
| EP3788078A1 (en) | 2021-03-10 |
| AU2019262167A1 (en) | 2020-12-10 |
| EP3788078A4 (en) | 2022-03-02 |
| BR112020022236A2 (en) | 2021-02-02 |
| MX2020011377A (en) | 2020-11-24 |
| US20210246205A1 (en) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL272877A (en) | Shp2 inhibitor compositions and methods for treating cancer | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| PT3496739T (en) | Compositions and methods for treating pulmonary hypertension | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL286350A (en) | Compositions and methods for treating cancer | |
| IL288914A (en) | Compositions and methods for treating cancer | |
| IL269637A (en) | Compositions and methods for treating synucleinopathies | |
| IL274837A (en) | Methods and compositions for treating cancers | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL285886A (en) | Compositions and methods for treating laminopathies | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| IL280413A (en) | Bismuth-thiol compositions and methods for treating wounds | |
| IL278814A (en) | Methods and compositions for treating pulmonary hypertension | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| IL285796A (en) | Methods and compositions for treating | |
| IL287982A (en) | Compositions and methods for treating cancer | |
| IL269550A (en) | Compositions and methods for treating synucleinopathies | |
| IL261010B (en) | Compositions and methods for treating chronic wounds | |
| IL277463A (en) | Compositions and methods for treating pruritus | |
| EP3262065C0 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
| SG11202010911WA (en) | Methods and compositions for treating chronic urticaria |